Table 1 Patient characteristics
From: Intensity modulated radiotherapy for elderly bladder cancer patients
| Â | IMRT | HT | All |
|---|---|---|---|
| Â | No. of patient (%) | ||
Age (years) | Â | Â | Â |
   Mean | 79.9 | 78.5 | 79.2 |
   Range | 66-90 | 65-89 | 65-90 |
Gender | Â | Â | Â |
   Male | 7 (77.8%) | 7 (70%) | 14 (73.7%) |
   Female | 2 (22.2%) | 3 (30%) | 5 (26.3%) |
Karnofsky performance status | Â | Â | Â |
   < 60 | 0 | 0 | 0 |
   ≥ 60 | 9 (100%) | 10 (100%) | 19 (100%) |
Pathology | Â | Â | Â |
   Urothelial carcinoma | 9 (100%) | 10 (100%) | 19 (100%) |
Tumor stage | Â | Â | Â |
   Stage I | 0 | 1 (10%) | 1 (5.3%) |
   Stage II | 2 (22.2%) | 2 (20%) | 4 (21.1%) |
   Stage III | 4 (44.4%) | 4 (40%) | 8 (42.1%) |
   Stage IV | 3 (33.3%) | 3 (30%) | 6 (31.6%) |
Primary Tumor stage | Â | Â | Â |
   T1-high risk | 0 | 1 (10%) | 1 (5.3%) |
   T2 | 2 (22.2%) | 3 (30%) | 5 (26.3%) |
   T3 | 5 (55.6%) | 3 (30%) | 8 (42.1%) |
   T4 | 2 (22.2%) | 3 (30%) | 5 (26.3%) |
Regional Lymph Node stage | Â | Â | Â |
   N0 | 6 (66.7%) | 7 (70%) | 13 (68.4%) |
   N1 | 2 (22.2%) | 1 (10%) | 3 (15.8%) |
   N2 | 1 (11.1%) | 2 (20%) | 3 (15.8%) |
Concurrent with chemotherapy | 3 (33.3%) | 6 (60%) | 9 (47.4%) |
Median dose for RT completion (range) (Gy) | 57.6 (45-64.8) | 57.6 (54-64.8) | 57.6 (45-64.8) |
Median time for RT completion (range) (wks) | 7 (6-11) | 6.5 (5-10) | 7 (5-11) |